Sartorius AG (SUVPF)

Sartorius AG (SUVPF) Healthcare & Pipeline Overview

Sartorius AG, established in 1870, is a global German supplier of advanced bioprocess solutions and laboratory products, serving life science research and biopharmaceutical manufacturing. Its extensive portfolio supports critical development, quality control, and production processes across the healthcare sector, driven by innovation in sophisticated tools and consumables.

What Is the Investment Thesis for SUVPF?

Sartorius AG (SUVPF) presents an investment profile centered on its critical role as a supplier to the growing biopharmaceutical industry, which is experiencing increasing demand for biologics and vaccines. The company's comprehensive portfolio, encompassing filtration, fermentation, fluid management, and lab products, positions it to capitalize on the ongoing expansion of biomanufacturing capabilities globally. With a market capitalization of $16.84B and a gross margin of 45.6%, Sartorius demonstrates strong operational efficiency within its specialized market. The P/E ratio of 91.3 indicates a premium valuation, reflecting investor confidence in its future growth prospects and market leadership. The company's beta of 1.45 suggests higher volatility relative to the broader market, which is typical for growth-oriented healthcare suppliers. Key growth catalysts include the continuous innovation in bioprocess technologies, the increasing complexity of new drug modalities requiring advanced analytical and manufacturing tools, and the expansion into emerging markets. Maintaining market share amidst potential increased competition in the bioprocessing market and adapting to evolving technological advancements are crucial for sustained value creation.

Based on FMP financials and quantitative analysis

SUVPF Key Highlights

• Sartorius AG maintains a robust Gross Margin of 45.6%, indicating strong profitability from its core bioprocess and laboratory product sales.
• The company commands a significant Market Cap of $16.84B, reflecting its substantial presence and investor valuation in the global healthcare sector.
• Sartorius AG's P/E ratio stands at 91.3, suggesting high investor expectations for future earnings growth, consistent with its position in a high-growth industry.
• With a Beta of 1.45, SUVPF exhibits higher price volatility compared to the overall market, which is characteristic of specialized growth companies in the healthcare industry.
• The company employs 13,573 individuals, underscoring its significant operational scale and global reach in delivering sophisticated bioprocess solutions and laboratory products.

Who Are SUVPF's Competitors?

SUVPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SUVPF's Key Strengths?

• Comprehensive portfolio of bioprocess solutions and laboratory products supporting critical life science research and biopharmaceutical manufacturing.
• Established global supplier with a long history (founded 1870) and extensive customer relationships.
• Strong operational efficiency demonstrated by a Gross Margin of 45.6%.
• Key position in a high-growth industry driven by increasing demand for biologics and vaccines.

What Are SUVPF's Weaknesses?

• High P/E ratio of 91.3 suggests premium valuation, potentially limiting upside if growth expectations are not met.
• Beta of 1.45 indicates higher stock price volatility compared to the broader market.
• Reliance on the biopharmaceutical industry's R&D cycles and funding, which can be subject to fluctuations.
• Unknown disclosure status for its OTC listing may impact investor confidence and transparency.

What Could Drive SUVPF Stock Higher?

• Continued increase in global R&D spending by biopharmaceutical companies, driving demand for Sartorius's advanced laboratory and bioprocess solutions.
• Regulatory approvals of new biologics and advanced therapies, which will necessitate increased manufacturing capacity and demand for Sartorius's production-scale equipment.
• Introduction of new, innovative single-use technologies or analytical platforms by Sartorius, enhancing its competitive edge and market share.
• Expansion of biomanufacturing capabilities in emerging markets, creating new sales opportunities for Sartorius's comprehensive product portfolio.

What Are the Key Risks for SUVPF?

• Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
• Rich valuation — a P/E of 91.3 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Increased competition in the bioprocessing market could lead to pricing pressures and erosion of market share.
• Rapid technological advancements in the life sciences sector require continuous and significant R&D investment, posing a risk if innovation lags.
• Global economic downturns or reduced funding for scientific research could negatively impact demand for laboratory products and services.
• Supply chain disruptions for critical raw materials or components could affect Sartorius's ability to manufacture and deliver products, impacting revenue and profitability.
• The unknown disclosure status on the OTC market may deter institutional investors and limit the company's access to broader capital markets.

What Are the Growth Opportunities for SUVPF?

• Growth opportunity 1: Increasing demand for biologics and advanced therapies presents a significant driver for Sartorius. The biopharmaceutical market is expanding rapidly, with new antibody therapies, gene therapies, and cell therapies requiring sophisticated bioprocess solutions. Sartorius's offerings in cell culture, fermentation, and filtration are critical for the development and manufacturing of these complex drugs. This trend is expected to continue for the foreseeable future, with the biologics market projected to reach hundreds of billions of dollars globally, ensuring sustained demand for Sartorius's specialized equipment and services.
• Growth opportunity 2: Expansion in single-use bioprocess technologies offers a substantial avenue for growth. Single-use systems are gaining traction in biopharmaceutical manufacturing due to their benefits in reducing contamination risks, accelerating production timelines, and lowering capital expenditure compared to traditional stainless steel facilities. Sartorius's portfolio includes various single-use bioreactors and fluid management solutions, positioning it to capture a larger share of this evolving market segment. The adoption of single-use technologies is a long-term trend, driven by efficiency and flexibility demands in biomanufacturing.
• Growth opportunity 3: The ongoing need for advanced laboratory products and services provides consistent growth. As life science research becomes more complex, there is a continuous demand for high-precision laboratory essentials, advanced analytics, and specialized testing services. Sartorius's offerings in weighing systems, pipetting, centrifuges, biosensors, and live-cell analysis platforms cater directly to these evolving research needs. The global laboratory equipment market is a multi-billion dollar industry, with continuous innovation driving upgrades and new purchases, supporting Sartorius's sustained revenue generation from this segment.
• Growth opportunity 4: Geographic expansion, particularly into emerging biopharmaceutical markets, represents a key growth driver. While Sartorius is a global supplier, there are still opportunities to deepen its penetration in regions where biopharmaceutical manufacturing infrastructure is developing rapidly. Countries in Asia, Latin America, and Eastern Europe are investing heavily in biotechnology, creating new demand for Sartorius's bioprocess solutions and laboratory products. Establishing stronger local presence and distribution networks in these high-growth regions can unlock significant market potential over the next decade.
• Growth opportunity 5: Continuous innovation and R&D in life science tools are crucial for maintaining a competitive edge and driving future growth. Sartorius's commitment to developing new technologies, such as advanced analytical platforms and optimized media formulations, ensures its products remain at the forefront of scientific discovery and industrial application. Investing in R&D allows the company to address unmet needs in bioprocessing, enhance product performance, and introduce novel solutions that can create new market segments. This innovation cycle is essential for long-term relevance and market leadership in the dynamic healthcare sector.

What Opportunities Does SUVPF Have?

• Continued growth in the global biopharmaceutical market, particularly in biologics and advanced therapies.
• Increasing adoption of single-use bioprocessing technologies for efficiency and flexibility.
• Expansion into emerging markets with developing biomanufacturing infrastructure.
• Strategic acquisitions or partnerships to broaden product offerings and technological capabilities.

What Threats Does SUVPF Face?

• Potential for increased competition in the bioprocessing market from existing players and new entrants.
• Rapid technological advancements requiring continuous investment in R&D to maintain market relevance.
• Regulatory changes or increased scrutiny in the pharmaceutical and life science sectors.
• Economic downturns or supply chain disruptions impacting global research and manufacturing activities.

What Are SUVPF's Competitive Advantages?

• Extensive and specialized product portfolio covering critical stages of bioprocessing and laboratory research, creating high switching costs for customers.
• Deep technical expertise and long-standing relationships with key players in the biopharmaceutical industry, built over 150 years.
• Continuous innovation and R&D investments in advanced analytics, bioprocess technologies, and specialized consumables, leading to proprietary solutions.
• Global presence and established supply chain networks, enabling widespread distribution and support for international clients.
• Compliance with stringent regulatory standards required in the healthcare and biopharmaceutical sectors, acting as a barrier to entry for new competitors.

What Does SUVPF Do?

Sartorius AG, a German company founded in 1870 and headquartered in Göttingen, has evolved into a global supplier of innovative bioprocess solutions and laboratory products and services. With a history spanning over 150 years, the company has established itself as a critical partner in the life science and biopharmaceutical industries. Its comprehensive portfolio is designed to support various stages of scientific endeavor, from fundamental life science research to large-scale biopharmaceutical manufacturing, quality control, and other applied industrial processes worldwide. Sartorius's offerings encompass a wide array of sophisticated tools and consumables. In Advanced Analytics, the company provides biosensors, label-free detection systems, Surface Plasmon Resonance (SPR) systems, live-cell analysis platforms, flow cytometry, and related reagents, enabling precise measurement and analysis. For Cell Culture and Fermentation, Sartorius supplies various bioreactors, including single-use, stainless steel, and benchtop models, alongside specialized media tailored for antibodies, recombinant proteins, stem cells, and viral vaccines. Essential reagents like buffers and microcarriers are also part of this segment. The Filtration and Separation division offers a comprehensive range of membranes, filter papers, syringe filters, and diverse filtration and ultrafiltration devices crucial for sterile processing, sample preparation, and clarification in sensitive applications. Laboratory Essentials include high-precision weighing and pipetting systems, centrifuges, industrial microbiology systems, and water purification units, forming the backbone of modern laboratories. Furthermore, Sartorius provides Process Solutions, integrating fluid management, process chromatography, and advanced analytical technologies with data analytics to optimize complex bioprocesses. Beyond its extensive product catalog, Sartorius delivers crucial support services, such as bioprocess development and engineering, protein expression system services, media and process optimization, comprehensive testing, instrument services, and validation assistance, solidifying its role as an end-to-end solutions provider in the global life science ecosystem.

What Products and Services Does SUVPF Offer?

• Sartorius AG supplies innovative bioprocess solutions for the development, quality assurance, and production of drugs and vaccines.
• The company provides a wide range of laboratory products and services for life science research and applied industries.
• They offer advanced analytics tools, including biosensors, label-free detection, and live-cell analysis platforms.
• Sartorius manufactures various bioreactors, such as single-use and stainless steel systems, along with specialized cell culture media.
• They provide comprehensive filtration and separation technologies, including membranes, filter papers, and ultrafiltration devices.
• The company supplies essential laboratory equipment like weighing and pipetting systems, centrifuges, and water purification units.
• Sartorius offers process solutions, including fluid management, process chromatography, and data analytics for bioprocessing.
• They provide crucial support services such as bioprocess development, media optimization, testing, and instrument validation.

How Does SUVPF Make Money?

• Sartorius generates revenue through the sale of its proprietary bioprocess solutions and laboratory products to pharmaceutical, biotechnology, and research institutions.
• The company earns income from providing specialized services, including bioprocess development, media optimization, and instrument maintenance and validation.
• Revenue is derived from a global customer base, leveraging its extensive product portfolio and technical expertise across various stages of drug discovery and manufacturing.
• A significant portion of its business involves recurring sales of consumables like cell culture media, filters, and reagents, which are essential for ongoing research and production.
• Sartorius benefits from long-term relationships with customers who rely on its integrated solutions for critical biopharmaceutical processes.

What Industry Does SUVPF Operate In?

Sartorius AG operates within the Medical - Instruments & Supplies industry, a vital segment of the broader Healthcare sector. This industry is characterized by continuous innovation, stringent regulatory requirements, and a high demand driven by advancements in life sciences and biopharmaceutical research. Sartorius is strategically positioned as a global supplier of essential bioprocess solutions and laboratory products, catering to the increasing need for specialized equipment and services in drug development, quality assurance, and production. The overall industry is experiencing growth fueled by the rising prevalence of chronic diseases, an aging global population, and the accelerating development of biologics and advanced therapies. Sartorius's comprehensive portfolio, which spans advanced analytics, cell culture, filtration, and laboratory essentials, allows it to serve a wide array of clients from academic research institutions to large pharmaceutical manufacturers. The competitive landscape includes both specialized niche players and larger diversified healthcare technology companies, with competition intensifying as demand for bioprocessing solutions continues to grow.

Who Are SUVPF's Key Customers?

• Biopharmaceutical companies engaged in drug development and manufacturing.
• Biotechnology firms focusing on research, development, and production of biologics.
• Academic and government research institutions conducting life science studies.
• Contract Development and Manufacturing Organizations (CDMOs) providing outsourced bioprocessing services.
• Quality control laboratories and other applied industries requiring precision laboratory equipment.

Company Profile

Sartorius AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Göttingen, DE. The company is led by CEO Michael Grosse. SUVPF has traded publicly since 2014.

ROE 6%Key Financial Metrics

Return on equity for Sartorius AG stands at 6.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.6%, showing how much profit it generates from its asset base. SUVPF trades at a trailing price-to-earnings ratio of 91.29, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.91 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 1.0%, the inverse of the P/E and a quick read on earnings relative to price.

SUVPF Valuation & Market Position

With a $16.84B market cap, Sartorius AG sits in the large-cap segment of the market. Relative to its peer group, SUVPF's quantitative score of 51/100 is roughly in line with the peer average of 56/100.

Quarterly Financial Performance: Sartorius AG

Revenue for Sartorius AG came in at $902.5M during Q1 2026, a 2.7% contraction versus the preceding quarter. The company recorded net income of $56.4M, with diluted EPS of $0.82. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SUVPF averaged $0.59 in diluted EPS.

F-Score 7/9Financial Health

Sartorius AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.34 places it in the grey zone, a middle ground that warrants monitoring.

0/8 beatsEarnings Track Record

Sartorius AG has missed Wall Street's EPS estimate in 8 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 44.9% below estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Sartorius AG revenue of about $3.74B for fiscal 2026, with EPS near $5.39. The estimate reflects 22 contributing analysts.

SUVPF Financials

SUVPF Latest News

SUVPF Analyst Consensus

SUVPF MoonshotScore

Common Questions About SUVPF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources